Turnstone Biologics CORP

Turnstone Biologics Corp. has completed its merger with XOMA Royalty Corporation, becoming a wholly-owned subsidiary and delisting from Nasdaq.

Turnstone Biologics Corp. has formally executed separation and consulting agreements with its Chief Executive Officer and Chief Operating Officer, detailing severance packages and transitional consulting roles.

Turnstone Biologics Corp. has filed an amendment to its merger agreement with XOMA Royalty Corporation, primarily to include the full forms of the Contingent Value Rights Agreement and Tender and Support Agreement, detailing the $0.34 cash per share plus CVR offer.

Turnstone Biologics Corp. has entered into a definitive merger agreement to be acquired by XOMA Royalty Corporation for $0.34 per share in cash plus one contingent value right, with the transaction expected to close in August 2025.

Turnstone Biologics announced its Q1 2025 financial results, highlighting a decrease in R&D expenses and net loss, while also revealing the exploration of strategic alternatives to maximize shareholder value.

Turnstone Biologics Corp. receives approval to transfer its listing to the Nasdaq Capital Market and gains an extension to meet minimum bid price requirements.

Turnstone Biologics Corp. is set to merge with XOMA Royalty Corporation, discontinuing all clinical programs and reducing its workforce to three employees, with a potential liquidation if the merger fails.

Turnstone Biologics discontinues clinical trials and seeks strategic alternatives due to financial constraints, raising concerns about its future.

Turnstone Biologics reported its Q3 2024 financial results, alongside a strategic pipeline prioritization and a 60% workforce reduction to focus on TIDAL-01.

Turnstone Biologics reports a net loss of $40.9 million for the first half of 2024, while highlighting positive preliminary data from its TIDAL-01 clinical trial.

Turnstone Biologics reported a net loss of $19.6 million for the first quarter of 2024, compared to a net income of $0.1 million for the same period in 2023, while continuing to advance its clinical programs.

Turnstone Biologics Corp. discontinues clinical studies and explores strategic alternatives to enhance stockholder value amid financial constraints and Nasdaq compliance challenges.

Turnstone Biologics' 10-K filing details its common stock structure, ongoing clinical trials for its Selected TIL therapies, and future development plans.

OrbiMed Advisors and OrbiMed Capital GP VI LLC disposed of their entire 3,099,265 shares of Turnstone Biologics common stock following a cash tender offer by XOMA Royalty Corporation.

Versant Ventures V, LLC and its affiliated entities have fully disposed of their common stock holdings in Turnstone Biologics Corp. following a tender offer.

Turnstone Biologics Director Jerel Davis reports the disposition of common stock holdings through various Versant entities as part of a cash tender offer by XOMA Royalty Corporation.

Turnstone Biologics Director Rishi Gupta disposed of over 3 million shares of common stock as part of a cash tender offer by XOMA Royalty Corporation.

Director Kanya Rajangam acquired 12,770 stock options in Turnstone Biologics Corp. on June 3, 2024.

Director Robert J. Gould acquired 12,770 stock options in Turnstone Biologics Corp. on June 3, 2024.

Turnstone Biologics Corp. has filed a definitive proxy statement with the SEC.

Turnstone Biologics Corp. will hold its annual meeting of stockholders virtually on June 3, 2024, to elect directors and ratify the selection of Ernst & Young LLP as the company's independent registered public accounting firm.

Versant entities report full divestment of Turnstone Biologics shares following its acquisition by XOMA Royalty Corporation.

Point72 Asset Management and its affiliates, including Steven A. Cohen, have reported a 0% beneficial ownership stake in Turnstone Biologics Corp. as of September 30, 2025.

FMR LLC and its affiliate Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.9% in Turnstone Biologics Corp.'s common stock as of March 31, 2025.